Loading…
Academic Journal
Minimal residual disease prognostic value for relapse-free survival of children with acute lymphoblastic leukemia treating according to ALL-MB-2002 protocol (monofactorial and multifactirial analysis)
N. N. Savva, O. V. Kras'ko, M. V. Belevtcev, V. P. Savitckiy, N. V. Migal, O. V. Aleinikova
Онкогематология, Vol 0, Iss 2, Pp 17-21 (2022)
Saved in:
| Title | Minimal residual disease prognostic value for relapse-free survival of children with acute lymphoblastic leukemia treating according to ALL-MB-2002 protocol (monofactorial and multifactirial analysis) |
|---|---|
| Authors | N. N. Savva, O. V. Kras'ko, M. V. Belevtcev, V. P. Savitckiy, N. V. Migal, O. V. Aleinikova |
| Publication Year |
2022
|
| Source |
Онкогематология, Vol 0, Iss 2, Pp 17-21 (2022)
|
| Description |
220 children with acute lymphoblastic leukemia (ALL) treated according to ALL-MB-2002 protocol are included in the study. Minimal residual disease (MRD) estimated in bone marrow by three-color flow cytometry on day 15 (n=99), day 36 (n=107) and before the maintenance therapy (n=60). Day 36 positive MRD level (≥0.01%) as one of unfavorable factors statistically significant worsening of relapse-free survival was revealed (log-rank test; р
|
| Document Type |
article
|
| Language |
Russian
|
| Publisher Information |
ABV-press, 2022.
|
| Subject Terms | |
